Antibacterial agents

Details Antibacterial agents Antibacterial agents

2001-01-12

2004-08-24

Solola, Taofiq (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S237800, C514S252120, C514S317000, C514S429000, C544S107000, C544S358000, C544S392000, C546S192000, C546S208000, C548S558000, C548S566000

Reexamination Certificate

active

06780858

ABSTRACT:

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
Not applicable
BACKGROUND OF THE INVENTION
Resistance to currently available antibiotics has created a need for new antibiotic agents. Infections, caused by organisms such as
Staphylococcus aureus, Pseudomonas aeruginosa, Enterococcus faecium
and
Enterococcus faecalis
, have become increasingly resistant to currently approved antibiotics. For example, significant clinical problems include methicillin-resistant strains of
S. aureus
, which are resistant to all current antibiotics except vancomycin (a drug of last resort because of severe side effects), and a vancomycin-resistant strain of
E. faecium enterococci
which is now found world-wide. Even community-acquired organisms such as
Streptococcus pneumoniae
are increasingly resistant to antimicrobial agents, with a significant number of isolates being resistant to penicillin and extended-spectrum cephalosporins.
The emergence and spread of resistant bacterial organisms are primarily caused by acquisition of drug resistance genes, resulting in a broad spectrum of antibiotic resistance (e.g., extended-spectrum cephalosporin-resistant mutant.beta.-lactamases found in several bacterial organisms). Genetic exchange of multiple-resistance genes, by transformation, transduction and conjugation; combined with selective pressures in settings such as hospitals where there is heavy use of antibiotic therapies, enhance the survival and proliferation of antimicrobial agent-resistant bacterial strains occurring by, e.g., spontaneous mutants. Although the extent to which bacteria develop resistance to antimicrobial drugs and the speed with which they do so vary with different types of drugs, resistance has inevitably developed to all antimicrobial agents (see Gold and Moellering, Jr., 1996, New Eng. J. Med., 335(19):1445-1453).
To prevent or delay the buildup of a resistant pathogen population, different chemicals that are effective against a particular disease-causing bacterium must be available. Thus, there is a need to identify compounds which can penetrate and specifically kill the pathogenic bacterial cell, or arrest its growth without also adversely affecting its human, animal, or plant host.
One avenue for accomplishing this task involves the use of compounds targeting RNA polymerase. Accordingly, what is needed in the art are new compounds which are effective inhibitors of bacterial RNA polymerase and which are useful as antibacterial agents. The present invention provides such compounds along with methods for their use.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides antibacterial compounds having the formula:
A—X—M—Y—B
or a pharmaceutically acceptable salt thereof, wherein the letters A and B each independently represent a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group. The letters X and Y each independently represent a group selected from:
with the proviso that at least one of X or Y is a bond. In the above group of radicals, the subscript m is 0, 1 or 2; the subscript n is 1 or 2; W is selected from O, N—OR
5
, N—NR
1
R
2
, N—NR
1
C(O)R
6
and N—OC(O)R
6
; wherein R
1
, R
2
, R
3
, and R
5
each independently represent H, (C
1
-C
6
)alkyl, aryl, aryl(C
1
-C
6
)alkyl, heteroaryl or heteroaryl(C
1
-C
6
)alkyl; R
4
represents H, OH, (C
1
-C
6
)alkyl, (C
1
-C
6
)alkoxy, amino, (C
1
-C
6
)alkylamino, di(C
1
-C
6
)alkylamino, (C
1
-C
6
)acylamino, or (C
1
-C
8
)heteroalkyl; and R
6
represents H, (C
1
-C
6
)alkyl, (C
1
-C
6
)alkoxy, amino, (C
1
-C
6
)alkylamino, di(C
1
-C
6
)alkylamino, or (C
1
-C
8
)heteroalkyl. Returning to formula I, the letter M is a divalent linking group selected from:
wherein the letter U represents a group selected from:
wherein R
7
and R
8
are independently H, OH, (C
1
-C
6
)alkyl, (C
1
-C
6
)alkoxy, amino, (C
1
-C
6
)alkylamino or di(C
1
-C
6
)alkylamino; R
9
is H, (C
1
-C
6
)alkyl, aryl, aryl(C
1
-C
6
)alkyl, heteroaryl or heteroaryl(C
1
-C
6
)alkyl; R
10
is H, (C
1
-C
6
)alkyl, aryl(C
1
-C
6
)alkyl or heteroaryl(C
1
-C
6
)alkyl; and R
11
and R
12
are independently H, (C
1
-C
6
)alkyl, aryl(C
1
-C
6
)alkyl, heteroaryl(C
1
-C
6
)alkyl, C(O)R
14
, C(O)OR
14
, C(O)—NR
14
R
15
, S(O)
2
R
13
or S(O)
2
NR
14
R
15
; wherein R
13
is (C
1
-C
6
)alkyl, (C
1
-C
6
)heteroalkyl, phenyl or substituted phenyl; and R
14
and R
15
are each independently H, (C
1
-C
6
)alkyl or (C
1
-C
6
)heteroalkyl.
In another aspect, the present invention provides pharmaceutical compositions comprising one or more of the above compounds in admixture with a pharmaceutically acceptable excipient.
In yet another aspect, the present invention provides methods for controlling bacterial growth on a surface comprising contacting the surface with a compound having the formula above.
In still another aspect, the present invention provides methods for treating or preventing bacterial growth in a subject by administering to the subject an effective amount of a compound having the formula above.


REFERENCES:
patent: 4243409 (1981-01-01), Schmidt et al.
Aurich, Hans G. et al., Aminyl oxides (nitroxides). XX. Formation of aminyl oxides in the reaction of nitrile oxides with hydroxylamines, Chem. Ber. (1975) XP002167476.
Chemical abstracts Servc XP002167484.
Chemical abstracts XP002167485.
Chemical abstracts XP002167486.
Chemical abstract XP002167487.
Chemical abstracts XP002167488.
Yousif, N.M. et al., Reactions of alpha., .bea. -spiroepoxyalkanones. Part IV. New and facile synthesis of tetrahydronaphthalen-2ol derivatives for biological evalutioan, Bul. Fac. Pharm. XP-001002117 (abstract) (1998).
Oyama, Hiroshi et al., Electrochemical manufacture of benzenecarboxylmidamide derivative. XP002167477 (abstract) and JP 01215994 A (Aug. 29, 1989).
Oyama, Hiroshi et al., Preparation of 1,2,4-oxadiazin-5-ones as agrochemical microbicides. XP002167478 (abstract) and JP 03 148267 A (Jun. 25, 1991).
Agirbas, Hikmet et al., A convenient synthesis of 3,4-disubstituted-1,2,4-thiadiazole-5(4H)-thiones XP002167479 (abstract) and Phosphorus, Sulfur silicon Relat. Elem. (1998).
Agirbas, Hikmet et al., Reation of substituted benzamide oximes with chloroacetyl chloride and thiophosgene, XP002167480 (abstract) and Phosphorus, Sulfur Silicon Relat. Elm. (1999).
Freccero, Mauro et al., Cycloadditions with trophane and its derivatives. 7. Reactions of o,o,′-disubstituted benzonitrile oxides with 8-azaheptafulvenes Heterocycles (1998), XP002167473.
Risitano F. et al., 5-exo-Trigonal cyclization and [3,5] Rearrangement of N-Aryl Benzamidoximes by Reaction with Nitrile Oxides, XP004105205.
Oyama, Hiroshi et al., Preparation of O-(acylalkyl) benzanilideoximes as agrochemial fungicides XP002167481 (abstract) and JP 01 034954 A (Feb. 6, 1989).
Beltrame, Paola et al., Kinetics of the acid-catalyzed addition of arylamines to aromatic nitrile oxides XP002167482 (abstract and Gazz. Chim. Ital. (1984).
August, Bernd et al., ESR spectroscopic detection of benzoxadiazinyl radicals, Tetrahedron Let. (1979), XP002167474.
Gilchrist, Thomas et al., Reversible cyclization of orgho-blocked N-arylnitroso imines, J. Chem. Soc., Chem. Commun. (1975) XP002167475.
Micromastoras, E.D. et al., Electron-impact induced fragmentatin of benzamidoximes XP002167483 (abstract) and Chem. Chron. (1974).

Affiliated with

Also associated with

Rating

Antibacterial agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibacterial agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibacterial agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3343399